Gene therapy

Current Problems in Surgery

Volumn 33, Issue 12, 1996, Pages 961-1041

  Tzeng, Edith ^a   Shears II, Lorry L ^b   Loize, Michael I ^c   Billiar, Timothy R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Department of Surgery and Molecular Genetics and Biochemistry Co Director ^*  (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; COMMUNICABLE DISEASE; GENE THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; LEGAL ASPECT; MEDICAL ETHICS; NEOPLASM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; STATISTICS; UNITED STATES;

ARTERIAL OCCLUSIVE DISEASES; CLINICAL TRIALS; COMMUNICABLE DISEASES; ETHICS, MEDICAL; GENE THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; NEOPLASMS; UNITED STATES;

EID: 0030457552     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-3840(05)80020-6     Document Type: Article

References (171)

1. Watson JD, Oilman M, Witkowski J, Zoller M. Recombinant DNA. 2nd ed. New York: Scientific American Books, 1992.
2. Mendel G. English translation of Mendel's experiments in plant hybridization. In: Peters JA, editor. Classic papers in genetics. Englewood Cliffs: Prentice-Hall, 1959.
3. Stevens NM. Studies in spermatogenesis with especial reference to the accessory [sex] chromosome. Cam Inst Wash 1905;36:1-32.
4. Chargaff E. Structure and function of nucleic acids as cell constituents. Fed Proc 1951:10:654-9.
5. Hershey AD, Chase M. Independent functions of viral protein and nucleic acid in growth of bacteriophage. J Gen Physiol 1952:36:39-56.
6. Watson JD, Crick FHC. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 1953:171:737-8.
7. Crick FHC, Watson JD. The complementary structure of deoxyribonucleic acid. Proc Roy Soc A 1954:223:80-96.
8. Meselson M, Stahl FW. The replication of DNA in a Escherichia coli. Proc Natl AcadSciUSA 1958:44:671-82.
9. Nishimura S, Jones DS, Khorana HG. The in vitro synthesis of a copolypeptide containing two amino acids in alternating sequence dependent upon a DNA-like polymer containing two nucleotides in alternating sequence. J Mol Biol 1965:13: 302-24.
10. Crick FHC. Codon-anticodon pairing: the wobble hypothesis. J Mol Biol 1966: 19:548-55.
11. 1. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981:290:457-65.
12. Meselson M,YuanR. DNA restriction enzyme fromE. coli. Nature 1968;217:1110-4.
13. Roberts RJ. Restriction and modification enzymes and their recognition sequences. Nucleic Acids Res 1983:11:r135-67.
14. Mertz JE, Davis RW. Cleavage of DNA by RI restriction endonuclease generates cohesive ends. Proc Natl Acad Sci U S A 1972:69:3370-4.
15. Cohen S, Chang A, Boyer H, Helling R. Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A 1973:70:3240-4.
16. Watanabe T. Infectious heredity of multiple drug resistance in bacteria. Bacteriol Rev 1963:27:87-115.
17. Cohen SN, Miller CA. Multiple molecular species of circular R-factor DNA isolated from Escherichia coli. Nature 1969:224:1273-7.
18. Blaitner FR. Williams BG, Blechl AE, et al. Charon phages: safer derivatives of bacteriophage lambda for DNA cloning. Science 1977:196:161-9.
19. Collins J, Hohn B. Cosmids: a type of plasmid gene cloning vector that is packageable in vitro in bacteriophage heads. Proc Natl Acad Sci U S A 1978;75:4242-6.
20. Sanger R, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977:74:5463-7.
21. Watson JD. The Human Genome Project: past, present, and future. Science 1990:248:44-9.
22. Cantor CR. Orchestrating the Human Genome Project. Science 1990:248:49-51.
23. Shapiro J. MacHattie L, Eron L, et al. Isolation of pure lac operon DNA. Nature 1969:224:768-74.
24. Gilbert W, Miiller-Hill B. Isolation of the lac repressor. Proc Natl Acad Sci U S A 1966:56:1891-8.
25. McClure WR. Rate-limiting steps in RNA chain initiation. Proc Natl Acad Sci U S A 1980:77:5634-8.
26. Youderian P, Bouvier S, Susskind M. Sequence determinants of promoter activity. Cell 1982:30:843-53.
27. Brown DD, Gurdon JB. High-fidelity transcription of 5S DNA injected into Xenopus oocytes. Proc Natl Acad Sci U S A 1977;74:2064-8.
28. Maniatis T, Goodbourn S, Fischer JA. Regulation of inducible and tissue-specific gene expression. Science 1987:236:1237-45.
29. Breathnach R, Mandell JL, Chambon P. Ovalbumin gene is split in chicken DNA. Nature 1977:270:314-9.
30. Saltzman AG, Weinmann R. Promoter specificity and modulation of RNA polymerase II transcription. FASEB J 1989;3:1723-33.
31. Shatkin AJ. Capping of eucaryotic mRNAs. Cell 1976;645-53.
32. Lim L. Canellakis ES. Adenine-rich polymer associated with rabbit reticulocyte messenger RNA. Nature 1970:227:710-2.
33. Maniatis T, Hardison RC, Lacy E, et al. The isolation of structural genes from libraries of eucaryotic DNA. Cell 1978:15:687-701.
34. Rabbitts TH. Bacterial cloning of plasmids carrying copies of rabbit globin messenger RNA. Nature 1976:260:221-5.
35. Geller DA. Billiar TR. Should surgeons clone genes? The strategy behind the cloning of the human inducible nitric oxide synthase gene. Arch Surg 1993; 128:1212-20.
36. Ingram VM. Gene mutations in human hemoglobin: the chemical difference between normal and sickle hemoglobin. Nature 1957:180:326-8.
37. Maniatis T, Jim GK, Efstradiadis A, Kafatos F. Amplification and characterization of beta-globin gene synthesized in vitro. Cell 1976:8:163-82.
38. Crow JF. Anecdotal, historical and critical commentaries on genetics. Genetics 1992:131:761-8.
39. Friedmann T. A brief history of gene therapy. Nat Genet 1992;2:93-8.
40. Kay ERM. Incorporation of deoxyribonucleic acid by mammalian cells in vitro. Nature 1961:191:387-8.
41. Bradley TR, Roosa RA, Law L. DNA transformation studies with mammalian cells in culture. J Cell Comp Physiol 1962:60:127-38.
42. Sambrook J, Westphal J, Srivansan PR, Dulbecco R. The integrated state of viral DNA in SV40-transformed cells. Proc Natl Acad Sci U S A 1968:59:1288-93.
43. Terheggen HG, Lowenthal A, Lavinha F, Colombo JP, Rogers S. Unsuccessful trial of gene replacement in arginase deficiency. J Exp Med 1975;119:1-3.
44. Wolff JA, Lederberg J. A history of gene transfer and therapy. 49n: Wolff JA, editor. Gene therapeutics: methods and applications of direct gene transfer. Boston: Birkhauser, 1994.
45. Friedmann T. Roblin R. Gene therapy for human genetic disease? Science 1972:175:949-55.
46. Cline MJ, Slang H, Mercola K, et al. Gene transfer in intact animals. Nature 1980:284:422-5.
47. Mercola KE, Stang HD, Browne J, Salser W, Cline MJ. Insertion of a new gene of viral origin into bone marrow cells of mice. Science 1980:208:1033-5.
48. Wade N. UCLA gene therapy racked by friendly fire. Science 1980:210:509-11.
49. Wade N. Gene therapy caught in more entanglements. Science 1981;212:24-5.
50. Wade N. Gene therapy pioneer draws mikadoesque rap. Science 1981;212:1253.
51. Anderson WF. Fletcher JC. Gene therapy in human beings: when is it ethical to begin? N Engl J Med 1980:303:1293-7.
52. Temin H. Mechanism of cell transformation by RNA tumor viruses. Annu Rev Microbio 1971:25:609-48.
53. Temin H. The DNA provirus hypothesis. Science 1976:192:1075-80.
54. Temin HM, Mizutani S. RNA-directed DNA polymerase in virions of Rous sarcoma virus. Nature 1970:226:1211-3.
55. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumor viruses. Nature 1970:226:1209-11.
56. Shimotohno K, Temin HM. Formation of infectious progeny virus after insertion of herpes simplex tymidine kinase gene into DNA of an avian retrovirus. Cell 1981:26:67-77.
57. Wei C. Gibson M, Spear PG, Scolnick EM. Construction and isolation of a transmissible retrovirus containing the src gene from Harvey Murine Sarcoma Virus and the thymidine kinase gene from herpes simplex virus type I. J Virol 1981 ;39:935-44.
58. Tabin CJ, Huffman JW, Goff SP, Weinberg RA. Adaptation of a retrovirus as a eucaryotic vector transmitting the herpes simplex thymidine kinase gene. Mol Cell Biol 1982:2:426-36.
59. Friedmann T. Gene therapy: fact and fiction. In: Biology's new approaches to disease. A Banbury Public Information Report. Cold Spring Harbor, NY, 1983.
60. Miller AD, Jolly DJ, Friedmann T, Verma IM. A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc NatlAcad Sci U SA 1983;80:4709-13.
61. Kantoff PW, Kohn DB, Mitsuya H, et al. Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1986:83:6563-7.
62. Weintraub HM. Antisense RNA and DNA. Sci Am 1990;262:40-6.
63. Rosenberg SA, Aebersold P, Cornelia K, et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
64. Culver KW. Berger M, Miller AD, Anderson WR, Blaese RM. Lymphocyte gene therapy for adenosine deaminase deficiency. Pediatr Res 1992;31:149A.
65. Anderson WF. Human gene therapy. Science 1992:256:808-13.
66. Varmus H. Retroviruses. Science 1988:240:1427-35.
67. Poiesx BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus panicles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980:77:7415-9.
68. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of aT-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983:220:868-71.
69. Bishop JM. The molecular genetics of cancer. Science 1987;235:305-11.
70. Miller AD. Retroviral vectors. CUIT Top Microbiol Immunol 1992:158:1-24.
71. Linial ML. Miller AD. Retroviral RNA packaging: sequence requirements and implications. Curr Top Microbiol Immunol 1990:157:125-52.
72. Brown PO. Bowerman B, Varmus HE. Bishop JM. Correct integration of retroviral DNA in vitro. Cell 1987:49:347-56.
73. Shih CC. Stoye JP. Coffin JM. Highly preferred targets for retrovirus integration. Cell 1988:53:531-7.
74. Van Beveren C. Verma IM. Homology among oncogenes. Curr Top Microbiol Immunol 1986; 123:73-98.
75. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983:33:153-9.
76. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986:6:2895-902.
77. Watanabe S, Temin HM. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol 1983:3:2241-9.
78. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci U S A 1984:81:6349-53.
79. Miller AD, Law MF, Verma IM. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol 1985:5:431-7.
80. Stoker AW. Bissell MJ. Development of avian sarcoma and leukosis virus-based vector-packaging cell lines. J Virol 1988:62:1008-15.
81. Danos O. Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 1988;85: 6460-4.
82. Rowe WP. Huebner RJ. Gilmore LK, Parrott RH, Ward TG. Isolation of a cyto-pathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953;84:570-3.
83. Stratford-Perricaudet LD, Perricaudet M. Gene therapy: the advent of adenovirus. In: Wolff JA, editor. Gene therapeutics: methods and applications of direct gene transfer. Boston: Birkhauser, 1994.
84. Straus SE. Adenovirus infections in humans. In: Ginsberg HS, editor. The adenoviruses. New York and London: Plenum Press, 1984.
85. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 1992;158:38-66.
86. Nevins JR. Regulation of early adenovirus gene expression. Microbiol Rev 1987;51 : 419-30.
87. Babiss LE, Ginsberg HS. Adenovirus type 5 early region Ib gene product is required for efficient shutoff of host protein synthesis. J Virol 1984:50:202-12.
88. Babiss LE, Ginsber HS, Darnell JE Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol 1985;5:2552-8.
89. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985;41:987-97.
90. Burgert HG, Maryanski JL, Kvist S. E3/19K protein of adnovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc Natl Acad Sci U S A 1987;84:1356-60.
91. Graham PL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-72.
92. Schneider MD, French BA. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation 1993;88:1937-42.
93. Grubb BR, Pickles RJ, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994;371:802-6.
94. Roizen B, Sears A. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, Chanock RM, et al., editors. Virology. 2nd ed. New York: Raven, 1990.
95. Glorioso JC, Coins WF, Meaney CA, Fink DJ, DeLuca NA. Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994;35:S28-34.
96. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. RNA complementary to a herpesvirus a gene mRNA is prominent in latently infected neurons. Science 1987;235:1056-9.
97. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992;158:97-129.
98. Lyerly HK, DiMaio JM. Gene delivery systems in surgery. Arch Surg 1993; 128:1197-206.
99. Graham FL, van der Eb AJ, Heijneker HL. Size and location of the transforming region in human adenovirus type 5 DNA. Nature 1974;251:687-90.
100. Kato S, Anderson RA, Camerini ORD. Foreign DNA introduced by calcium phosphate is integrated in repetitive DNA elements of the mouse L cell genome. Mol Cell Biol 1986;6:1787-95.
101. Mannino RJ, Gould-Fogerite. Liposome mediated gene transfer. BioTechniques 1988;6:682-90.
102. Feigner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987;84:7413-7.
103. Nabel EG, Plautz G, Nabel GJ. Gene transfer in primary cultures of human hepatocytes. In Vitro Cell Dev Biol 1992;12:101-4.
104. Nabel EG, Yang Z, Liptay S, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimai hyperplasia in vivo. J Clin Invest 1993;91:1822-9.
105. Capecchi M. High efficiency transformation by direct microinjection into cultured mammalian cells. Cell 1980;22:479-88.
106. Shigekawa K, Dower WJ. Electroporation of eukaryotes and prokaryotes: a general approach to the introduction of macromolecules into cells. BioTechniques 1988;6: 742-51.
107. Sun WH, Burkholder JK, Sun J, et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci U S A 1995;92:2889-93.
108. Ferry N, Duplessis O, Houssin D, Danos O, Heard JM. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci U S A 1991;88:8377-81.
109. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-4.
110. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995;92:1137-41.
111. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995:267:518-22.
112. Takekoshi KJ, Oh YH, Westerman KW, London IM, Leboulch P. Retroviral transfer of a human -globin/(-globin hybrid gene linked to locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease. Proc Natl Acad Sci U S A 1995:92:3014-8.
113. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
114. Stewart C, Taylor NA, Green 1C, Docherty K, Bailey CJ. Insulin-releasing pituitary cells as a model for somatic cell gene therapy in diabetes mellitus. J Endocrinol 1994:142:339-43.
115. Vitullo JC, Aron DC, Miller RE. Control of insulin gene expression: implications for insulin gene therapy. J Lab Clin Med 1994;124:328-34.
116. Tahara H, Mueller GM, Ricordi C, Robbins PD, Lotze MT. Islet cell transplantation facilitated by gene transfer. Transplant Proc 1992;24:2975-6.
117. Lashford L. Gene therapy for cancers. Arch Dis Childhood 1994;71:485-7.
118. Skuse OR, Ludlow JW. Tumor suppressor genes in disease and therapy. Lancet 1995:345:902-6.
119. Herrmann F. Cancer gene therapy: principles, problems, and prospective. J Mol Med 1995;73:157-63.
120. Blaese RM, Ishii-Morita H, Müllen C, et al. In situ delivery of suicide genes for cancer treatment. Eur J Cancer 1994;30A:1190-3.
121. Smythe JA, Symonds G. Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection. Inflamm Res 1995;44:11-5.
122. Leitersdorf E, Tobin EJ, Davignon J, Hobbs H. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990;5: 1014-23.
123. Sprecher DK, Hoeg JM, Schaifer EJ, et al. The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. Metabolism 1985;34:294-9.
124. Bilheimer DW. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984;311:1658-64.
125. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia. Atherosclerosis 1980;6:261-8.
126. Kaleko M, Garcia JV, Miller AD. Persistent gene expression after retroviral gene transfer into liver cells in vivo. Hum Gene Ther 1991;2:27-32.
127. Ferry N, Duplessis O, Houssin D, Danos O, Heard J. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci U S A 1991;88:8377-81.
128. Wilson JM, Johnston DE, Jefferson DM, Mulligan RC. Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1988;85:4421-5.
129. Grossman M, Râper S, Wilson JM. Transplantation of genetically modified autologous hepatocytes in non-human primates. Hum Gene Ther 1992;2:501-10.
130. Grossman M, Râper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nat Genet 1994;6:335-41.
131. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med 1988;318:1734-7.
132. Tzeng e, Shears LL, Robbins PD, et al. Vascular gene transfer of the human indueible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Molecular Medicine 1996;2:211-25.
133. McNamara DB, Bedi B, Aurora H, et al. L-arginine inhibits balloon catheter induced intimai hyperplasia. Biochem Biophys Res Commun 1993;193:291-6.
134. Guo JP, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimai injury. Circ Res 1994;75:77-84.
135. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A 1993;90:3491-5.
136. Tzeng E, BilliarTR, Robbins PD, Loftus M, Stuehr DJ. Expession of human inducible nitric oxide synthase in a tetrahydrobiopterin (BH4)-deficient cell line: BH4 promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci U S A 1995:92:11771-5.
137. Nakayama DK, Geller DA, DiSilvio M, et al. Tetrahydrobiopterin synthesis and inducible nitric oxide production in pulmonary artery smooth muscle. Am J Physiol 1994;266:L455-60.
138. Takeshita S, Gal D, Leclerc G, et al. Increased gene expression after liposomemediated arterial gene transfer associated with intimai smooth muscle cell proliferation: in vitro and in vivo findings in a rabbit model of vascular injury. J Clin Invest I994;93:652-61.
139. Whartenby KA, Abboud CN, Marrogi AJ, Ramesh R, Freeman SM. The biology of cancer gene therapy. Lab Invest 1995:72:131-45.
140. Forni G, Parmiani G, Guarini A, Roa R. Gene transfer in tumor therapy. Ann Oncol 1994;5:789-94.
141. Vieweg J, Gilboa E. Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest 1995:13:193-201.
142. Freeman SM, Zwiebel JA. Gene therapy for cancer. Cancer Invest 1993;11:676-88.
143. Schirrmacher V. Perspectives of immunotherapy and gene therapy. J Cancer Res Clin Oncol 1995;121:443-51.
144. Fujiquara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 1994;6:96-105.
145. Lotze MT, Rubin JT. Gene therapy of cancer: a pilot study of IL-4 gene modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 1994;5:41-56.
146. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. Clinical protocal: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995 ;6:1607-24.
147. Modestie A, Masuelli L, Modica A, et al. Ultrastructural evidence of the mechanisms responsible for interleukin-4 activated rejection of a spontaneous murine adenocarcinoma. Int J Cancer 1993;53:988-93.
148. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 interplays potent antitumor activity in vivo. Cell 1989;57:503-12.
149. Golumbek PT, Lazenby AJ, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991:254:713-6.
150. Lotze MT. Role of IL-4 in the antitumor response. In: Spits H, editor. Interleukin-4: structure and function. Boca Raton, Fla.: CRC Press, 1992:237-62.
151. Wong HL, Lotze MT, Wahl LM, Wahl SM. Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J Immunol 1992;148:2118-25.
152. Chen JY, Funk WD, Wright WE. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 1993;8:2159-66.
153. Fujiwara T, Grimm EA, Mukhopadhyay T. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;53:4129-33.
154. Mitsudomi T, Steinberg SM, Oie HK, et al. ras gene mutation in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.
155. Mickisch GH, Alsentijevich I, Schoenlein PV, et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long term protect against the myelosuppressive effect of chemotherapy in mice. Blood 1992;79:1084-93.
156. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR-1. Science 1992;257:99-103.
157. Berger EM, Gert BM. Genetic disorders and the ethical status of germ-line gene therapy. J Med Philos 1991:16:667-83.
158. Hughes J. Enbracing change wih all four arms: a post-humanist defense of genetic engineering. http://ccme-mac4.bsd.uchicago.edu/JCV/JGeneTech.html.
159. Elias S, Annas G. Somatic and germline therapy. In: Gene mapping: using law and ethics as guides. Oxford University Press, New York: 1992.
160. Areen J, King P. Legal regulation of human gene therapy. Hum Gene Ther 1990;1:151-61.
161. Palmer JG. Liability considerations presented by human gene therapy. Hum Gene Ther 1991:2:235-242.
162. Epstein SL. Regulatory concerns in human gene therapy. Hum Gene Ther 1991:2:243-9.
163. Cohen-Haguenauer O. Regulation of gene therapy in Europe: a current statement including reference to US regulations. Eur J Cancer 1994;30A:1193-1201.
164. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with Wiskott-Aldrich syndrome. Lancet 1968;2:1364-6.
165. Kredich NM, Hershfield MS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1989:1045-75.
166. Isner JM, Walsh K, Symes J et al. Arterial gene therapy for therapeutic angiogensis in patients with peripheral arterial disease. Circulation 1995;91:2687-92.
167. Takeshita S, Zhen LP, Brogi E, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischémie hind limb model. J Clin Invest 1994;93:662-70.
168. Evans CH. Transferring therapeutic genes to joints: a Pittsburgh idea. Pittsburgh Orthopedics Journal 1992;3:130-1.
169. Bandara G. Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992:11:227-31.
170. Brenner MK, Rill DR, Moen RC et al. Gene marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993:341:85-6.
171. Lotze MT. Molecular biology and clinical applications to cancer. In: Daley JM, editor. Current opinion in general surgery. New York: Current Science, 1994:245-54.